Oppenheimer & Co’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.92M | Buy |
4,308
+36
| +0.8% | +$16.8K | 0.02% | 607 |
|
|
2025
Q4 | $1.94M | Buy |
4,272
+668
| +19% | +$288K | 0.03% | 554 |
|
|
2025
Q3 | $1.41M | Sell |
3,604
-237
| -6% | -$99K | 0.02% | 735 |
|
|
2025
Q2 | $1.71M | Sell |
3,841
-2,360
| -38% | -$1.09M | 0.02% | 628 |
|
|
2025
Q1 | $3.01M | Sell |
6,201
-1,428
| -19% | -$665K | 0.05% | 427 |
|
|
2024
Q4 | $3.07M | Sell |
7,629
-5,499
| -42% | -$2.55M | 0.05% | 422 |
|
|
2024
Q3 | $6.11M | Sell |
13,128
-601
| -4% | -$289K | 0.09% | 239 |
|
|
2024
Q2 | $6.44M | Buy |
13,729
+1,099
| +9% | +$477K | 0.1% | 220 |
|
|
2024
Q1 | $5.28M | Buy |
12,630
+754
| +6% | +$319K | 0.09% | 260 |
|
|
2023
Q4 | $4.83M | Buy |
11,876
+1,568
| +15% | +$579K | 0.09% | 261 |
|
|
2023
Q3 | $3.58M | Buy |
10,308
+1,797
| +21% | +$628K | 0.07% | 302 |
|
|
2023
Q2 | $3M | Buy |
8,511
+675
| +9% | +$227K | 0.06% | 368 |
|
|
2023
Q1 | $2.47M | Sell |
7,836
-7,563
| -49% | -$2.27M | 0.05% | 395 |
|
|
2022
Q4 | $4.45M | Sell |
15,399
-1,088
| -7% | -$332K | 0.1% | 245 |
|
|
2022
Q3 | $4.77M | Buy |
16,487
+945
| +6% | +$272K | 0.11% | 225 |
|
|
2022
Q2 | $4.38M | Buy |
15,542
+972
| +7% | +$260K | 0.09% | 255 |
|
|
2022
Q1 | $3.8M | Buy |
14,570
+6,805
| +88% | +$1.62M | 0.07% | 339 |
|
|
2021
Q4 | $1.71M | Buy |
7,765
+4,340
| +127% | +$844K | 0.03% | 563 |
|
|
2021
Q3 | $621K | Buy |
3,425
+1,344
| +65% | +$262K | 0.01% | 928 |
|
|
2021
Q2 | $420K | Sell |
2,081
-2,954
| -59% | -$618K | 0.01% | 1108 |
|
|
2021
Q1 | $1.08M | Sell |
5,035
-2,332
| -32% | -$512K | 0.02% | 680 |
|
|
2020
Q4 | $1.74M | Buy |
7,367
+2,375
| +48% | +$545K | 0.04% | 480 |
|
|
2020
Q3 | $1.36M | Sell |
4,992
-3,712
| -43% | -$1.02M | 0.03% | 480 |
|
|
2020
Q2 | $2.53M | Buy |
8,704
+903
| +12% | +$245K | 0.07% | 320 |
|
|
2020
Q1 | $1.86M | Buy |
7,801
+2,313
| +42% | +$531K | 0.06% | 356 |
|
|
2019
Q4 | $1.2M | Sell |
5,488
-64
| -1% | -$13K | 0.03% | 561 |
|
|
2019
Q3 | $941K | Buy |
5,552
+826
| +17% | +$146K | 0.03% | 616 |
|
|
2019
Q2 | $867K | Sell |
4,726
-1,774
| -27% | -$310K | 0.02% | 637 |
|
|
2019
Q1 | $1.2M | Sell |
6,500
-1,315
| -17% | -$243K | 0.03% | 537 |
|
|
2018
Q4 | $1.29M | Sell |
7,815
-3,687
| -32% | -$639K | 0.04% | 446 |
|
|
2018
Q3 | $2.22M | Buy |
11,502
+3,302
| +40% | +$588K | 0.06% | 372 |
|
|
2018
Q2 | $1.39M | Sell |
8,200
-1,090
| -12% | -$169K | 0.04% | 484 |
|
|
2018
Q1 | $1.51M | Buy |
9,290
+4,131
| +80% | +$675K | 0.04% | 471 |
|
|
2017
Q4 | $773K | Buy |
5,159
+714
| +16% | +$106K | 0.02% | 699 |
|
|
2017
Q3 | $676K | Buy |
+4,445
| New | +$669K | 0.02% | 741 |
|
Other funds holding VRTX
VCM
VPM
Oppenheimer & Co's VRTX Position: Q1 2026 in Review
Oppenheimer & Co increased its Vertex Pharmaceuticals (VRTX) stake by 0.84% in Q1 2026, buying an estimated $16.8K and bringing the position to 4,308 shares worth $1.92M. The position accounts for 0.02% of the portfolio, ranked #607.
Oppenheimer & Co first reported a position in VRTX in Q3 2017 and has held it in 35 quarters since. The position peaked at $6.44M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Oppenheimer & Co held 4,308 shares of Vertex Pharmaceuticals worth $1.92M as of Q1 2026.
- Oppenheimer & Co bought 36 Vertex Pharmaceuticals shares in Q1 2026, an estimated $16.8K.
- Vertex Pharmaceuticals made up 0.02% of Oppenheimer & Co's portfolio in Q1 2026, its #607 holding.
- Oppenheimer & Co first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
- Oppenheimer & Co's Vertex Pharmaceuticals position peaked at $6.44M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.